Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


CSL joins gene therapy surge

Posted 15 October 2020

One of the first gene therapies to provide long-term benefits to patients with haemophilia B could launch as early as 2022, CSL CEO Paul Perreault has announced at the company's AGM.

Under a deal brokered with Dutch biotech uniQure in June this year, CSL has exclusive global rights to the new therapy which has the potential to offer long-term improvements with just one dose.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended